Sign In
Buy SAVA
$1.96
+0 (+0%)
At Close: Jun 03, 2026
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
11:51am, Wednesday, 24'th Dec 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inve
Cassava Announces Agreement to Settle Securities Class Action Litigation
08:00am, Tuesday, 23'rd Dec 2025
AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatment
FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold
11:31am, Friday, 19'th Dec 2025
Cassava Sciences Inc. (NASDAQ: SAVA) received a formal letter from the U.S. Food and Drug Administration (FDA) related to the company's trial for simufilam
Cassava Pops After CEO Buys 150,000 Shares
07:39am, Tuesday, 25'th Nov 2025
Cassava Sciences (SAVA) jumped roughly 10% in after-hours trading on Monday after investors spotted a notable insider move from the top. An SEC filing showed CE
Comparing Cassava Sciences (NASDAQ:SAVA) and Carisma Therapeutics (NASDAQ:CARM)
02:46am, Wednesday, 05'th Nov 2025
Carisma Therapeutics (NASDAQ: CARM - Get Free Report) and Cassava Sciences (NASDAQ: SAVA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare
Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights
04:05pm, Wednesday, 22'nd Oct 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) breached their fiduciary duti
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
08:00am, Wednesday, 22'nd Oct 2025
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatment
Cassava Reports Q2 2025 Financials Results and Provides Business Update
07:30am, Thursday, 14'th Aug 2025
AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatment
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
07:30am, Thursday, 07'th Aug 2025
AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigat
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
07:30am, Monday, 04'th Aug 2025
AUSTIN, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel treatment
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
07:00am, Monday, 30'th Jun 2025
Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data from 1,929 patient Phase 3 program AUSTIN, Texas, June 30, 2025
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
07:30am, Thursday, 01'st May 2025
As SVP, Neuroscience, Dr. Bordey will lead Cassava's ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially add
AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investiga
Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround
10:35am, Tuesday, 01'st Apr 2025
The heavy selling pressure might have exhausted for Cassava Sciences (SAVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street an
Is the Future Bleak for SAVA Stock Following Another Setback?
11:01am, Monday, 31'st Mar 2025
The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with uncertain growth prospects.
